Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations (MAV-RAPA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02042326|
Recruitment Status : Recruiting
First Posted : January 22, 2014
Last Update Posted : August 10, 2018
The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM).
Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.
|Condition or disease||Intervention/treatment||Phase|
|Arteriovenous Malformations||Drug: Sirolimus||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations|
|Actual Study Start Date :||September 12, 2014|
|Estimated Primary Completion Date :||September 2020|
|Estimated Study Completion Date :||September 2020|
Experimental: Sirolimus treatment
Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml.
The starting dose will be 2 mg per day, and will be adapted every week for one month.
The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment.
For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
Other Name: Rapamune
- Treatment efficacy at M12 [ Time Frame: After 12 months of treatment ]
The efficacy of treatment is a composite criteria based on:
- The proportion of patients with no evolution of the AVM during the study period,
- The proportion of patients with a reduction in tumor volume of the AVM at least 30% of CT Angiography (CTA) criteria during the first year of the study (comparison of the volume of the AVM a year versus pre-inclusion).
- Treatment efficacy at M3 [ Time Frame: After 3 months of treatment ]
- Treatment efficacy at M6 [ Time Frame: After 6 months of treatment ]
- Treatment efficacy at M9 [ Time Frame: After 9 months of treatment ]
- Treatment tolerability [ Time Frame: One year ]Number and description of serious advent events
- Treatment Impact on Quality of life [ Time Frame: Before treatment initiation and after 12 months of treatment ]Quality of life will be assessed before and at the end of the first year of treatment using a questionnaire given to patients. There is no questionnaire specifically tailored to vascular malformations in the literature. Thus the investigators adapted a document based on an evaluation of the quality of life for survivors of burn injury.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02042326
|Contact: Bernard DEVAUCHELLE, MD, PhDfirstname.lastname@example.org|
|Contact: Sylvie TESTELIN, MD, PhDemail@example.com|
|UCL||Not yet recruiting|
|Amiens, France, 80000|
|Principal Investigator: Bernard DEVAUCHELLE, MD, PhD|
|Sub-Investigator: Sylvie TESTELIN, MD, PhD|
|CHU Bordeaux||Not yet recruiting|
|Bordeaux, France, 33000|
|Dijon, France, 21000|
|Contact: Pierre VABRES, MD PhD|
|Principal Investigator: Pierre VABRES, MD PhD|
|CHRU Lille||Not yet recruiting|
|Lille, France, 59000|
|Lyon, France, 69000|
|Contact: Pierre BRETON, MD PhD firstname.lastname@example.org|
|Contact: Laurent GUIBAUD, MD PhD email@example.com|
|Principal Investigator: Pierre BRETON|
|Principal Investigator: Laurent GUIBAUD|
|APHM||Not yet recruiting|
|Marseille, France, 13000|
|Contact: Stéphanie MALLET, MD firstname.lastname@example.org|
|Principal Investigator: Jean-Michel BARTOLI|
|Sub-Investigator: Stéphanie MALLET, MD|
|CHU Montpellier||Not yet recruiting|
|Montpellier, France, 34000|
|CHU Nancy||Not yet recruiting|
|Nancy, France, 54000|
|CHU Nice||Not yet recruiting|
|Nice, France, 06000|
|APHP||Not yet recruiting|
|Paris, France, 75000|
|CHU Strasbourg||Not yet recruiting|
|Strasbourg, France, 67000|
|CHU Tours||Not yet recruiting|
|Tours, France, 37000|
|Study Director:||Bernard DEVAUCHELLE, MD, PhD||CHU Amiens|
|Study Chair:||Emmanuel MORELON, MD, PhD||HCL Lyon|